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ABSTRACT
Background: Stroke secondary to atrial fibrillation has been 
associated to a high risk of permanent, severe disability, and 
high early mortality, and therefore its effective prevention is 
of paramount importance. Warfarin therapy reduces the risk of 
stroke by 60%, however, half of the patients with atrial fibrillation 
do not receive anticoagulation. Left atrial appendage closure 
has emerged as an alternative strategy for stroke prevention. 
Methods: Patients with atrial fibrillation and CHADSVASc 
score ≥ 2, not eligible for anticoagulation, were submitted to 
left atrial appendage closure using the WatchmanTM device. 
The procedure was performed under general anesthesia and 
was guided by transesophageal echocardiography. Results: Of 
the 11 selected patients, 2 were not treated due to thrombi 
presented prior or during the procedure and before device 
implantation. Mean age was 74 ± 5.1 years, 66% were male, 
CHA2DS2-VASc score was 4 ± 1.4, HASBLED score was 3.4 
± 1.1, 77% had contraindications or had unfavorable social 
conditions for anticoagulation. Technical success was 100% 
and complete occlusion was obtained in all of the cases, with 
a mean fluoroscopic time of 22.1 ± 10.8 minutes, and no 
hospital complications. At a follow-up of 78.3 ± 41.5 days, 
there were no clinical events but one patient had thrombus 
formation on the device and received anticoagulation for 3 
months. Conclusions: Left atrial appendage closure with the 
WatchmanTM device is feasible and may be a good alternative 
therapy for stroke prevention in patients with atrial fibrillation 
and restrictions for anticoagulation. 
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RESUMO
Oclusão Percutânea do Apêndice Atrial Esquerdo 
com Prótese Watchman®
Introdução: O acidente vascular cerebral secundário à fibrilação 
atrial tem sido associado a taxas de mortalidade e de incapa-
cidade permanente elevada, porquanto sua prevenção eficaz 
é importante. O tratamento com varfarina diminui em 60% o 
risco de acidente vascular cerebral; todavia, até metade dos 
pacientes com fibrilação atrial não faz uso da anticoagulação. 
A oclusão do apêndice atrial esquerdo surgiu como estratégia 
alternativa para prevenção do acidente vascular cerebral. Méto-
dos: Foram selecionados pacientes com fibrilação atrial, escore 
de CHA2DS2-VASc ≥ 2, não elegíveis para anticoagulação, 
para se submeterem ao fechamento percutâneo do apêndice 
atrial esquerdo com a prótese WatchmanTM. O procedimento 
foi realizado sob anestesia geral e guiado por ecocardiografia 
transesofágica. Resultados: Dos 11 pacientes selecionados, 2 
não foram tratados por apresentarem trombo pré ou durante 
o procedimento, antes do implante do dispositivo. A idade 
foi de 74 ± 5,1 anos, 66,6% eram do sexo masculino, com 
escores CHA2DS2-VASc de 4 ± 1,4 e HAS-BLED de 3,4 ± 
1,1, 77% tinham contraindicação ou condições sociais desfa-
voráveis para utilizarem a anticoagulação. O sucesso técnico 
foi de 100%, sendo alcançada a oclusão completa em todos 
os casos, com tempo médio de fluoroscopia de 22,1 ± 10,8 
minutos e ausência de complicações hospitalares. No segui-
mento de 78,3 ± 41,5 dias, não ocorreram desfechos clínicos, 
mas um paciente apresentou trombo no dispositivo e recebeu 
anticoagulação por 3 meses. Conclusões: A oclusão percutânea 
do apêndice atrial esquerdo com dispositivo WatchmanTM é 
factível e pode ser uma alternativa atrativa na prevenção de 
acidente vascular cerebral nos pacientes com fibrilação atrial 
e limitação para anticoagulação.
DESCRITORES: Fibrilação atrial. Apêndice atrial. Acidente 
vascular cerebral. 
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S troke is the leading cause of cardiovascular mortality and morbidity, affecting nearly 800,000 indivi-duals annually in the United States. Its incidence 
increases substantially with age, attributable to atrial 
fibrillation (AF) in approximately 1.5% of patients aged 
<  60 years and in more than 20% of patients aged > 
80 years.1 The absolute risk of systemic embolism in 
nonvalvular AF depends on the presence of associated 
factors such as hypertension, heart failure, diabetes 
mellitus, female gender, and a history of thrombo-
embolic events, measured in clinical practice through 
the CHA2DS2-VASc score.2
Vitamin K antagonists are the most commonly 
used therapy for the prevention of thromboembolic 
events in AF, as they have proven efficacy, with a 
60% reduction in the risk of stroke.3 However, ap-
proximately 50% of eligible individuals do not use 
this class of drugs, due to limitations related to risk of 
hemorrhage, previous hemorrhage, treatment interrup-
tion or withdrawal, interaction with other drugs and 
foods, the strict therapeutic window, and the need for 
careful monitoring of prothrombin time.4 Recent clini-
cal trials have demonstrated the efficacy and safety 
of new anticoagulant agents when compared with 
warfarin, but with an annual risk of bleeding ranging 
from 1.4% to 3% throughout life, they have excluded 
patients at high risk of bleeding.5,6 
In Latin America, unfavorable social conditions, 
low educational levels, and little access to health care 
make the use of anticoagulants more difficult, even in 
patients without contraindications. The development of 
per cutaneous interventional strategies, such as occlusion 
of the left atrial appendage (LAA), appears to be an at-
tractive alternative for the prevention of thromboembolism 
in nonvalvular AF. The aim of this study was to describe 
cases of the LAA closure with the WatchmanTM prosthesis 
in individuals with difficulty and/or contraindication to 
oral anticoagulation.
METHODS
Study population
The Hemodynamics Services of hospitals José 
Carrasco Arteaga and Santa Inés, both located in 
Cuenca, Ecuador, started their training programs for 
percutaneous occlusion of the LAA in August 2013, 
in association with physicians of Hospital San Vicente 
de Paul of Medellin, Colombia. The criteria for patient 
selection included presence of chronic or nonvalvular 
paroxysmal AF, CHA2DS2-VASc score ≥ 2, previous 
thromboembolic events, presence of thrombus in the 
LAA in spite of adequate anticoagulation (but with 
resolution before the intervention), and limitations to 
anticoagulation due to clinical contraindications or due 
to social, cultural, or educational factors that prevented 
the prescription.
Device
The WatchmanTM (Boston Scientific Corporation, 
Natick, MA) is a parachute-shaped device, percutan eously 
deployed in the LAA. It consists of a self-expanding 
nitinol metal frame, which is covered by a polyester 
mesh. The physical properties of nitinol allow the device 
to adapt to the contours of the LAA after implantation. 
The structure has ten anchors that help it to attach 
inside the LAA. The polyester membrane covering the 
device on the atrial side prevents the escape of blood 
clots to the left atrium. The WatchmanTM device is cur-
rently available in five sizes (21, 24, 27, 30, and 33 
mm) and allows the occlusion of LAAs measuring up 
to 31 mm in diameter. The delivery system has three 
components: the 14 F access sheath (WatchmanTM Ac-
cess System), the delivery catheter preloaded with the 
device (WatchmanTM Delivery System), and a transeptal 
puncture sheath.
PrOcEDurE
Before the procedure, patients received acetylsalicylic 
acid (ASA) at a dose of 100 mg/day and clopidogrel at 
a dose of 75 mg/day. However, patients with image of 
thrombus in the LAA received warfarin (international 
normalized ratio [INR] of 2 to 3) and ASA for at least 
15 days before the procedure and were then submit-
ted to transesophageal echocardiography (TEE) one 
day prior to implantation, to verify the presence of 
thrombi. Under general endotracheal anesthesia and 
TEE monitoring, the LAA was measured, as well as its 
inlet orifice and depth.
Vascular access was obtained with 7 F and 5 F 
introducers in the right femoral vein and right femoral 
artery, respectively. The atrial septum was punctured 
at a low and posterior position, followed by systemic 
intravenous anticoagulation. With the help of a pigtail 
catheter, manual angiograms were obtained in the right 
anterior oblique view with cranial and caudal angulation 
for anatomic delineation and measurement of structures. 
The 14 F double-curve sheath was advanced into the 
dominant lobe of the LAA under the pigtail catheter 
and a new angiography was performed to establish the 
relative depth of radiopaque markers, which helped in 
prosthesis size selection.
Simultaneously, guided by TEE, the inlet orifice of 
the LAA and its depth were evaluated at cuts of 0°, 
45°, 90°, and 135°. The device was selected in ac-
cordance with the table provided by the manufacturer 
and based on the inlet orifice and the depth of the 
LAA primary lobe.
Once the desired depth was achieved with the 
double-curve sheath, the device, which was preloaded 
in the 12 F delivery catheter, was advanced up to its 
extremity and the cable was pushed to align the radi-
opaque markers of the delivery catheter and of the 14 
F sheath. Then, the 14 F catheter (WatchmanTM Access 
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System) was slowly retracted, keeping the delivery 
system fixed inside the LAA. While holding the cable, 
the delivery system was slowly withdrawn along the 14 
F sheath, thus exposing and configuring the prosthesis 
in the LAA.
After the device was deployed, adequate positioning 
of the prosthesis was confirmed by TEE and measure-
ments were performed of the shoulders of the largest 
prosthesis diameter, at cuts of 0°, 45°, 90°, and 135° 
to establish the optimum percentage of compression 
(8% to 20% of the original diameter). Proper anchor-
age was tested with gentle push-and-pull movements 
of the delivery wire (tug test). Control angiography with 
color Doppler was performed to confirm the absence 
of flow within the LAA; counterclockwise movements 
were also performed to release the device.
Post-procedure
Patients were extubated in the hemodinamic labora-
tory and transferred to the intermediate care unit. They 
were discharged from the hospital 48 hours later than 
the intervention, after being assessed through TEE and 
receiving ASA 100 mg/day indefinitely and clopido-
grel 75 mg/day, maintained for six months. In patients 
with evidence of LAA thrombus before the procedure, 
warfarin associated with ASA (81 mg) was maintained 
for 45 days, followed by dual antiplatelet therapy. A 
clinical follow-up was scheduled at the end of the first 
month and then every three months after the procedure. 
Control with TEE was scheduled to be performed at 45 
days, six months, and one year after the intervention.
clinical outcomes
The events of interest for this analysis were divided 
into safety and efficacy outcomes. Regarding safety, the 
following were considered: pericardial effusion with 
tamponade or need for intervention; stroke associated 
with the procedure; device embolization; and severe 
bleeding (gastrointestinal or intracranial). Regarding 
efficiency, the incidence of cardiac death, stroke, or 
thromboembolic events during follow-up were evaluated. 
Continuous variables were described as maximum 
and minimum values, as well as means and standard 
deviations. Categorical variables were described as 
percentages.
rESuLTS
Eleven patients were selected for LAA closure after 
consultation with the heart team. In the analysis using 
the initial TEE, LAA thrombi were detected in three 
patients who had their procedures postponed for two 
to three months in order to receive warfarin associated 
with ASA. Two patients responded to treatment and 
were maintained in the series; the third was definitely 
excluded due to the persistence of the thrombus in the 
LAA. Another patient had thrombus formation immediately 
after the atrial septum puncture, and thus the procedure 
was interrupted. Thus, nine patients underwent device 
implantation, of which 66.6% were males, with mean 
age of 74 ± 5.1 years. The social status of the study 
group was unfavorable, as 77.7% lived in rural areas, 
77.7% had only elementary school education or were 
illiterate, and 55.5% had been attended to at a medical 
institution less than three times a year – factors that 
were considered when indicating device implantation. 
The mean CHA2DS2-VASc score was 4 ± 1.4, and the 
mean HAS-BLED score was 3.4 ± 1.1 (Table 1).
Except for one case, all others had arterial hyperten-
sion; 77% of patients had previous bleeding, 55% had 
difficult-to-control INR, and 44% were taking medications 
that increased the risk of bleeding (Table 2).
The success rate for this procedure was 100%, as 
complete occlusion was attained, as well as absence 
of residual flux in all cases. The mean procedure time 
was 42.8 ± 13.2 minutes and mean fluoroscopy time 
was 22.1 ± 10.8 minutes (Table 3).
All patients showed a favorable evolution after 
the procedure, with no immediate clinical events, nor 
during the mean follow-up of 78.3 ± 41.5 days. Two 
patients received warfarin after device implantation, 
which was maintained for 45 days until the TEE was 
performed, when dual antiplatelet therapy was prescribed 
for another six months. The remaining patients received 
dual antiplatelet therapy with clopidogrel 75 mg per 
day, for six months, and acetylsalicylic acid 100 mg 
per day indefinitely.
One patient had a giant thrombus in the LAA before 
the procedure, which resolved with anticoagulation. The 
patient then underwent a successful intervention, but 
developed a thrombus above the device 55 days after 
implantation, identified at the control TEE. The patient 
remained asymptomatic and received enoxaparin 80 mg 
every 12 hours and ASA 81 mg for one month, and 
was then resubmitted to TEE, showing a large decrease 
(> 70%) in thrombotic burden (Figures 1-3).
DIScuSSION
The implantation of the WatchmanTM device for LAA 
occlusion in patients at high risk of thromboembolic 
events and difficulty or contraindication to the use 
of anticoagulants has shown to be feasible and safe. 
These outcomes are the result of the initial experience 
in Ecuador with the use of this device, and are part of 
a program of training and accreditation for percutan-
eous LAA occlusion of the Hemodynamics Services of 
hospitals José Carrasco Arteaga and Santa Inés.
International guidelines for the management of 
nonvalvular AF recommend anticoagulation as the 
treatment of choice in the prevention of stroke in the 
case of CHA2DS2-VASc score ≥ 2, which represents 
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TABLE 1  
Clinical characteristics
Patient
Age 
(years)
Chronic atrial 
fibrillation
Resides 
in a rural 
area
Outpatient 
follow-up  
< 3/year
Primary
Education
or illiteracy
CHA2DS2-
VASc
Score
HAS-BLED 
Score
1 78 + + + + 2 3
2 74 + + + + 5 4
3 72 + + – + 4 4
4 71 + + – – 2 3
5 75 + – – + 3 3
6 80 + + + + 5 3
7 72 + + + – 4 3
8 80 + + – ++ 6 2
9 64 + – + 5 6
Table 2  
Risk factors for thromboembolic and hemorrhagic phenomena
Patient
Arterial 
hypertension
Diabetes 
mellitus HF
Previous 
stroke, TIA, or 
thromboembolic 
phenomenon
Coronary 
or vascular 
disease
Severe  
previous 
hemorrhage
Difficult-
to-control 
INR
Use of 
medications 
that predispose 
to bleeding
1 – – – – – – + –
2 + – – + – + + –
3 + – + + – + – +
4 + – – – + + + +
5 + – – – – + – –
6 + – + + – – + –
7 + + – – + + – +
8 + – + + – + – –
9 + + + + – + + +
HF, heart failure; TIA, transient ischemic attack; INR, international normalized ratio.
TABLE 3  
Characteristics of the procedure
Patient
Ostium 
(mm)
Depth of left  
atrial appendage 
(mm)
Device 
size 
(mm)
Percentage  
of compression 
(%)
Residual  
shunt  
> 2 mm
Time of 
procedure
(minutes)
Time of 
fluoroscopy
(minutes)
1 21 26.4 24 4.8 – 58 35.2
2 17 19 21 23.8 – 36 9.7
3 18 26 24 15.8 – 39 14.1
4 16.7 21 21 18.1 – 33 18.2
5 28 33.7 30 9 – 35 24.1
6 20 28.8 27 9.2 – 39 14.7
7 19 26.3 24 9.1 – 48 32.3
8 25 21 30 10 – 69 38.5
9 24 29.2 27 17.7 – 28 12.5
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two-thirds of the population with AF.7 However, 50% 
of patients with anticoagulation indication, even in de-
veloped countries, receive no treatment due to absolute 
or relative contraindications, concerning the patient’s or 
the physician’s fear of causing iatrogenic hemorrhage.4 
This group of patients is unprotected from future occur-
rence of stroke, with a probability of development of 
permanent disability or death in up to 70% of cases. 
Additionally, a Swedish registry showed that the rate of 
permanent anticoagulation with warfarin, as secondary 
prevention for individuals who had a stroke, was 45% 
in up to two years.8 
The present group of patients had elevated calculated 
risk of thromboembolic events (mean CHA2DS2-VASc 
score of 4), associated with low social status and level of 
health education, which led to the consideration of the 
procedure as a suitable alternative, although there were 
no contraindications for anticoagulation in some cases. 
The efficacy and safety of percutaneous LAA occlu-
sion with the WatchmanTM prosthesis as an alternative to 
anticoagulation in patients without contraindications were 
demonstrated in two clinical trials and several observa-
tional studies, which included over 2,000 patients. The 
emblematic trial was the PROTECT-AF, which included 
707 patients with nonvalvular AF and CHA2DS2-VASc 
score ≥ 1, randomly divided into a 2:1 non-inferiority 
model – device vs. warfarin with target INR of 2-3. The 
study demonstrated that the device was not inferior to 
warfarin and was more effective in preventing ischemic 
events at the four-year follow-up. However, in the safety 
analysis, the WatchmanTM prosthesis showed a higher 
number of early complications related to the procedure, 
especially pericardial effusion requiring intervention.9 
The CAP Registry study was started later, aiming to 
evaluate the safety the procedure and factors related 
to the surgeon’s experience and the prosthesis. When 
comparing the PROTECT-AF study (542 patients) and 
A
C
B
D
Figure 1 – Transesophageal echocardiography images. (A) Left atrial appendage with large thrombus inside, affecting the edge of the left superior 
pulmonary vein (arrow). (B) Left atrial appendage after 55 days of anticoagulation, showing thrombus resolution and measurement of the inlet orifice. 
(C) Device adequately deployed without residual shunt. (D) Presence of thrombus located in the prosthesis, above the site of the release system 
connection, visualized 72 days after the procedure (arrow).
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the CAP Registry (460 patients) in relation to safety 
outcomes (which included bleeding, pericardial effusion, 
stroke, and device migration), there was a significant 
decrease in the procedure-related rate of complica-
tions, from 7.7% to 3.7 % (p = 0.007). In addition, the 
incidence of pericardial effusion decreased during the 
first seven days after implantation, from 5.0% to 2.2% 
(p = 0.018), and the rate of procedure-related stroke 
of 0.9% was reduced to zero (p = 0.039).10
A second prospective randomized clinical trial, 
similar to the PROTECT-AF, was the PREVAIL study, 
which focused on the analysis of early events related 
to the procedure and the surgeons’ experience, which 
showed a high procedure success rate and easily reached 
the limit of non-inferiority concerning safety events.11 
As occurred with other interventional procedures, there 
was a significant improvement in the safety of LAA oc-
clusion with the WatchmanTM device concomitant with 
increasing experience of surgeons.10-12
The present study showed satisfactory initial re-
sults of the clinical outcomes regarding safety of the 
prosthesis and intervention in procedures performed in 
a hospital familiarized with structural procedures and 
under the supervision of certified physicians. At the 
follow-up, one patient had a thrombus in the device, 
which raises questions with regard to its incidence, its 
clinical implication, and its management. The PROTECT-
AF study reported an incidence of thrombus adhered 
to the prosthesis of 4.2%. However, the calculated 
incidence of thromboembolic events was 0.3 events 
per 100 patients/year – a fact that did not negatively 
affect the overall results of the WatchmanTM group.9,13 
However, long-term clinical outcomes associated with 
the presence of thrombus in the device are yet to 
be clarified. It has been hypothesized that the site of 
insertion of the release cable screw has thrombogenic 
potential. A second hypothesis refers to the triangle 
not covered by the WatchmanTM prosthesis between the 
proximal portion of the device and the upper edge of 
the pulmonary vein, which could contain LAA trabecular 
tissue and generate thrombi. A registry showed three 
cases of thrombus formation in the WatchmanTM device, 
just above the screw insertion site, respecting the edge 
of the pulmonary vein. There were no thromboembolic 
phenomena in this group of patients.12 In the present 
A B C
D E
Figure 2 – Angiographic images in the right anterior oblique view (30°) caudal (20°). (A) Measurement of left atrial appendage. (B) Start of device 
release. (C) Release > 50%. (D) Full release of the WatchmanTM device with adequate positioning. (E) Angiographic control showing slight residual shunt.
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patient, the thrombus was similarly located, above and 
at the center of the device, without involving the triangle 
on the upper edge of the pulmonary vein. There were 
no important events, but it was necessary to initiate 
and maintain anticoagulation for three months, even 
though there was no clinical evidence for it.
In order to establish the safety and efficacy of the 
WatchmanTM device in patients with anticoagulation 
contraindications and/or difficulty, the ASAP study was 
developed, which included 150 patients with nonval-
vular AF and mean CHA2DS2-VASc score of 2.8. After 
the procedure, patients received ASA and clopidogrel 
continuously for six months. After a follow-up period 
of 176.9 patient-years, the observed rate of ischemic 
stroke was 1.7% per year and the presence of thrombus 
in the device was 4.0%, despite not receiving antico-
agulation in the first 45 days.13 
New oral anticoagulants have recently been evalu-
ated in large scale clinical trials showing similar or even 
superior effectiveness when compared to warfarin, but 
with incidence of bleeding identical to that of warfa-
rin (2.1% to 3.6%), in addition to risk of hemorrhagic 
events in the long term.5,6
The situation of the healthcare system in the pres-
ent study’s region is a challenge to appropriate treat-
ment and strict control of anticoagulation, with either 
warfarin or new oral anticoagulants, due to limitations 
arising from access to medical care, health education, 
high cost, and the availability of new drugs. There-
fore, the use of devices for LAA occlusion is a more 
expensive, albeit valid alternative for patients at high 
risk of bleeding and thromboembolic events. There is 
no doubt that it is essential to emphasize the need to 
redouble efforts to improve medical treatment based on 
Figure 3 – Transesophageal echocardiogram images after anticoagulation for 30 days. Left atrial appendage 116 days after the procedure, showing 
significant reduction in thrombotic burden (arrows).
Quizhpe et al. 
Left Atrial Appendage Closure
Rev Bras Cardiol Invasiva. 
2014;22(1):56-63
63
the use of anticoagulation, and to reserve percutaneous 
intervention only for cases in whom this strategy fails.
Study limitations
The sample size was small, which limits the evalu-
ation of clinical outcomes, but the safety of the pro-
cedure was demonstrated, as no short-term complications 
were observed.
cONcLuSIONS
Initial experience with percutaneous occlusion of 
the LAA has shown to be a safe and effective alterna-
tive therapy in the prevention of thromboembolic events 
in patients with nonvalvular atrial fibrillation in the 
short-term follow-up.
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